BLA 020032 · Abbvie
Survanta
Beractant · Intratracheal · Surfactant
NovelOrphanLast checked: Nov 19, 2026Latest source record: Jul 15, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1991
Jul 1, 1991
Approved uses
1
Original approval plus efficacy supplements
Registered trials
13
4 Phase 3, 0 recruiting
FAERS reports
369
362 serious, 222 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 15, 2020.
INDICATIONS AND USAGE SURVANTA is indicated for prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 1, 1991 Original approval · Type 1 - New Molecular Entity
1 products under this application
- SURVANTA · BERACTANT 25MG/ML · SUSPENSION, INTRATRACHEAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Beractant" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm NeonatesPivotal-lookingStatus unknown
Ramesh K AgarwalAcademic, hospital or other
NCT02774044 · 900 participants (planned) · Start Jun 2016 · Primary completion Feb 2019
Drug: Cadisurf; Survanta · For: Respiratory Distress Syndrome
- Exosurf Neonatal and Survanta for Treatment of Respiratory Distress SyndromePivotal-lookingCompleted
NICHD Neonatal Research NetworkResearch network
NCT01203358 · 617 participants · Start Jan 1991 · Primary completion Jan 1992
Drug: Exosurf; Survanta · For: Infant, Newborn; Infant, Low Birth Weight; Infant, Small for Gestational Age and 2 more
Sites: Palo Alto, California; New Haven, Connecticut; Washington D.C., District of Columbia · 13 sites in all
- A Multicenter, Randomized, Open Label Trial of a New Animal Extracted Surfactant to Treat RDS in Preterm InfantsPivotal-lookingCompleted
University of Sao PauloAcademic, hospital or other
NCT02305160 · 327 participants · Start Apr 2005 · Primary completion May 2006
Drug: Butantan; Control · For: Respiratory Distress Syndrome
Sites: Vitória da Conquista, Brazil; Brasília, Brazil; Goiânia, Brazil · 30 sites in all
- Prevention of Chronic Lung Disease (CLD) in Preterm InfantsPivotal-lookingStatus unknown
China Medical University, ChinaAcademic, hospital or other
NCT00883532 · 300 participants (planned) · Start Apr 2009 · Primary completion Dec 2012
Drug: budesonide; surfactant and air (placebo) · For: Respiratory Distress Syndrome; Chronic Lung Disease of Prematurity
Sites: Taichung, China
- Aerosolized Surfactant in Neonatal RDSPivotal-lookingCompleted
Sood, Beena G., MD, MSIndividual
NCT02294630 · 159 participants · Start Dec 2014 · Primary completion Jul 2019
Drug: Surfactant · For: Respiratory Distress Syndrome, Newborn
Sites: Detroit, Michigan
Dr. Sami Ulus Children's HospitalAcademic, hospital or other
NCT01852461 · 92 participants · Start Aug 2011 · Primary completion Dec 2012
Drug: Beractant; Poractant alfa · For: Poor Peripheral Perfusion
Universitas IndonesiaAcademic, hospital or other
NCT07725575 · 86 participants · Start Nov 1, 2024 · Primary completion Apr 24, 2025
Drug: Experimental · For: Bronchopulmonary Dysplasia (BPD)
Sites: Jakarta, Indonesia
- Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight InfantsPivotal-lookingTerminated
NICHD Neonatal Research NetworkResearch network
NCT00005774 · 61 participants · Start May 2000 · Primary completion Jul 2002
Drug: Early surfactant; Standard practice · For: Infant, Newborn; Respiratory Distress Syndrome; Respiratory Insufficiency
Sites: Birmingham, Alabama; Palo Alto, California; New Haven, Connecticut · 13 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pulmonary haemorrhage126
- death54
- neurodevelopmental disorder36
- pneumothorax34
- drug ineffective33
- sepsis19
- neonatal respiratory distress syndrome17
- endotracheal intubation complication16
- neonatal disorder16
- oxygen saturation decreased16
- respiratory failure15
- acute respiratory distress syndrome14
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 14 |
| 2005 | 18 |
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 12 |
| 2009 | 8 |
| 2010 | 5 |
| 2011 | 18 |
| 2012 | 15 |
| 2013 | 33 |
| 2014 | 70 |
| 2015 | 15 |
| 2016 | 17 |
| 2017 | 33 |
| 2018 | 27 |
| 2019 | 16 |
| 2020 | 16 |
| 2021 | 8 |
| 2022 | 12 |
| 2024 | 8 |
| 2025 | 10 |
| 2026 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Less invasive beractant administration in preterm infants: a pilot study.
Ramos-Navarro C, Sánchez-Luna M, Zeballos-Sarrato S, et al. · Clinics (Sao Paulo) 2016 · Controlled Clinical Trial
- Exogenous surfactant use in neonates.
Ishisaka DY · Ann Pharmacother 1996 · Clinical Trial, Review
- A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome.
Malloy CA, Nicoski P, Muraskas JK · Acta Paediatr 2005 · Clinical Trial, Comparative Study
- Beractant and poractant alfa in premature neonates with respiratory distress syndrome: a systematic review of real-world evidence studies and randomized controlled trials.
Sánchez Luna M, Bacher P, Unnebrink K, et al. · J Perinatol 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study.
Sehgal SS, Ewing CK, Richards T, et al. · J Natl Med Assoc 1994 · Clinical Trial, Randomized Controlled Trial
- Recent clinical trials of surfactant treatment for neonates.
Halliday HL · Biol Neonate 2006 · Meta-Analysis
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.